On the lookout for some news whilst perusing the 100+ page Form 10-K annual report filed by Replidyne (NASDAQ: RDYN) with the SEC on Friday I found the information provided on the regulatory process to be just a fantastic overview. So with some minor tweaks and a sincere appreciation to the folks in Louisville what [...]